<unk>  was the first histone deacetylase inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL on October 6, 2006. It also failed to demonstrate efficacy in treating acute myeloid leukemia in a phase II study.
Vorinostat
Febuxostat
Carfilzomib
Sunitinib
Ixazomib
Tazarotene
Pomalidomide
Gilteritinib